2023
DOI: 10.21203/rs.3.rs-2453552/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

PCSK9 inhibitor cooperatively with high triglyceride induces adverse pregnancy outcomes by impairing mitochondrial function

Abstract: The two monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), namely evolocumab and alirocumab, were first approved by the U.S. Food and Drug Administration (FDA) in 2015. PCSK9 inhibitor (PCSK9i) has served as a viable new therapeutic option to lower cholesterol levels and associated cardiovascular events. However, a better understanding of safety issue of PCSK9i is necessarily needed. We present here an increased risk of adverse pregnancy outcomes, including stillbirths and e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 47 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?